BR112022015172A2 - Metabólitos de ácidos graxos alfa-hidroxilados, usos médicos dos mesmos e uso como biomarcadores - Google Patents

Metabólitos de ácidos graxos alfa-hidroxilados, usos médicos dos mesmos e uso como biomarcadores

Info

Publication number
BR112022015172A2
BR112022015172A2 BR112022015172A BR112022015172A BR112022015172A2 BR 112022015172 A2 BR112022015172 A2 BR 112022015172A2 BR 112022015172 A BR112022015172 A BR 112022015172A BR 112022015172 A BR112022015172 A BR 112022015172A BR 112022015172 A2 BR112022015172 A2 BR 112022015172A2
Authority
BR
Brazil
Prior art keywords
fatty acids
alpha
metabolites
biomarkers
medical uses
Prior art date
Application number
BR112022015172A
Other languages
English (en)
Portuguese (pt)
Inventor
Vicente Escribá Ruiz Pablo
Torres Canalejo Manuel
Busquets Xaubet Xavier
Lladó Cañellas Victoria
Fernández García Paula
Ana Rosselló Castillo Catalina
Parets Barrios Sebastià
Beteta Gobel Roberto
Cano Urrego Emilce
Arbona González Laura
Rodríguez Lorca Raquel
Cabot Bauzá Juan
Millares Pizà Marc
Original Assignee
Univ Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES202030070A external-priority patent/ES2846824B2/es
Priority claimed from ES202031155A external-priority patent/ES2911474B2/es
Application filed by Univ Illes Balears filed Critical Univ Illes Balears
Publication of BR112022015172A2 publication Critical patent/BR112022015172A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03Monocarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022015172A 2020-01-29 2021-01-28 Metabólitos de ácidos graxos alfa-hidroxilados, usos médicos dos mesmos e uso como biomarcadores BR112022015172A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES202030070A ES2846824B2 (es) 2020-01-29 2020-01-29 Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
EP20382145 2020-02-28
ES202031155A ES2911474B2 (es) 2020-11-17 2020-11-17 Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
PCT/ES2021/070068 WO2021152201A2 (es) 2020-01-29 2021-01-28 Metabolitos de ácidos grasos alfa-hidroxilados, usos médicos de los mismos y uso como biomarcadores

Publications (1)

Publication Number Publication Date
BR112022015172A2 true BR112022015172A2 (pt) 2022-10-11

Family

ID=77078835

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015172A BR112022015172A2 (pt) 2020-01-29 2021-01-28 Metabólitos de ácidos graxos alfa-hidroxilados, usos médicos dos mesmos e uso como biomarcadores

Country Status (12)

Country Link
US (1) US20230097753A1 (https=)
EP (1) EP4098649A4 (https=)
JP (1) JP7736313B2 (https=)
KR (1) KR20220132552A (https=)
CN (1) CN115052852A (https=)
AU (2) AU2021212330A1 (https=)
BR (1) BR112022015172A2 (https=)
CA (2) CA3166307C (https=)
CL (1) CL2022001985A1 (https=)
IL (1) IL295120A (https=)
MX (1) MX2022009035A (https=)
WO (1) WO2021152201A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3105521A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonimidamide compounds as inhibitors of interleukin-1 activity
ES2982396A1 (es) * 2023-03-14 2024-10-15 Veritas Therapeutics S L 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1147221B (de) * 1958-06-28 1963-04-18 Dr Rer Nat Gernot Grimmer Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der Pentadecen- und Heptadecensaeuren
DE1195296B (de) * 1958-06-28 1965-06-24 Dr Gernot Grimmer Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der cis-9-Pentadecensaeure und der cis-9-Heptadecensaeure
GB1156465A (en) * 1967-02-16 1969-06-25 Unilever Ltd Prostaglandins
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9926833D0 (en) * 1999-11-15 2000-01-12 Univ Sunderland Compositions
DE102007055344A1 (de) * 2007-11-19 2009-05-20 K. D. Pharma Bexbach Gmbh Neue Verwendung von Omega-3-Fettsäure(n)
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
KR20120065276A (ko) 2009-05-29 2012-06-20 뉴 챕터, 인코포레이티드. 지질 조성을 조정하기 위한 조성물 및 방법
CN102276444B (zh) * 2011-05-04 2013-10-09 厦门大学 脂肪酸类化合物及其制备方法与应用
ES2401629B1 (es) 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2014113584A1 (en) * 2013-01-16 2014-07-24 Rhode Island Hospital Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
US20150173410A1 (en) * 2013-12-19 2015-06-25 Change Cola, Inc. Beverage comprising omega fatty acid
JP2016222590A (ja) * 2015-05-29 2016-12-28 国立大学法人東京海洋大学 脂肪酸の同位体標識化合物の製造方法およびその方法により得られた脂肪酸の同位体標識化合物、ならびに診断薬
WO2019241728A1 (en) * 2018-06-15 2019-12-19 Youhealth Biotech, Limited Composition and methods for modulation of elovl2

Also Published As

Publication number Publication date
IL295120A (en) 2022-09-01
CA3233141A1 (en) 2021-08-05
JP7736313B2 (ja) 2025-09-09
CN115052852A (zh) 2022-09-13
EP4098649A2 (en) 2022-12-07
US20230097753A1 (en) 2023-03-30
EP4098649A4 (en) 2024-04-17
MX2022009035A (es) 2022-08-11
AU2023248158B2 (en) 2025-11-27
WO2021152201A2 (es) 2021-08-05
AU2021212330A1 (en) 2022-09-22
CA3166307A1 (en) 2021-08-05
CL2022001985A1 (es) 2023-02-03
WO2021152201A3 (es) 2021-09-23
AU2023248158A1 (en) 2023-11-02
KR20220132552A (ko) 2022-09-30
CA3166307C (en) 2024-05-21
JP2023518640A (ja) 2023-05-08

Similar Documents

Publication Publication Date Title
Blanco-Cabra et al. Novel oleanolic and maslinic acid derivatives as a promising treatment against bacterial biofilm in nosocomial infections: an in vitro and in vivo study
BR112021022789A2 (pt) Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
CR20210578A (es) Derivados de ácido itacónico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunotaria indeseable
BR112022012637A2 (pt) Composto de piridazinil-tiazolcarboxamida, composição farmacêutica e inibidor da dgk ¿ que compreendem o mesmo e uso do dito composto para tratar câncer relacionado à ativação das células imunes ou câncer tendo resistência à terapia com anticorpo anti-pd-1 / anticorpo anti-pd-l1
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
CO2022010915A2 (es) Formulaciones farmacéuticas
MX2023008469A (es) Oligonucleotidos de doble hebra modificados.
CR20210201A (es) Nuevos compuestos antihelmínticos
BR112015029309A2 (pt) derivados de polimixina e seu uso em terapia de combinação junto com antibióticos diferentes
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112013003186A2 (pt) composições e métodos para tratamento de doença cardiovascular
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
BR112022015172A2 (pt) Metabólitos de ácidos graxos alfa-hidroxilados, usos médicos dos mesmos e uso como biomarcadores
CO2020001242A2 (es) Dihidrooxadiazinonas
BR112022018929A2 (pt) Inibidores da ciclofilina e seus usos
BR112022002720A2 (pt) Formulações de conjugados de benzazepinas e usos das mesmas
BR112022015153A2 (pt) Cepa de cutibacterium acnes e seus usos médicos
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
BR112022001341A2 (pt) Inibidores de enzima
BR112020024412A8 (pt) Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
UY29639A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos
BR112022008497A2 (pt) Derivados terapêuticos da interleucina-22

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]